Clinical Trial Detail

NCT ID NCT03179943
Title Overcoming Chechkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

transitional cell carcinoma

Therapies

Atezolizumab + Guadecitabine

Age Groups: senior adult

No variant requirements are available.